*History of SARS-CoV-2 infection in the past 6 months*Experiencing measured fever (>38 degrees) or other signs or symptoms consistent with COVID-19*Known medical history of active liver disease*Chronic Kidney Disease or have known moderate to severe renal impairment*Known human immunodeficiency virus (HIV) infection with a viral load greater than 400 copies/mL within the last 6 months or taking prohibited medications for HIV treatment*Suspected or confirmed concurrent active systemic infection*Active cancer requiring treatment with prohibited medication*Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4*Has received approved, authorized, or investigational anti-SARS-CoV-2 mAb, convalescent plasma, other drugs for treatment of COVID-19, or other anti-SARS-CoV-2 biologic products within 6 months of screening*Has received any SARS-CoV-2 vaccine within 6 months prior to screening or is expected to receive a SARS-CoV-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments through Day 38*Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19*Known or prior participation in this trial or another trial involving PF-07321332*Females who are pregnant or breastfeeding

*History of SARS-CoV-2 infection in the past 6 months*Experiencing measured fever (>38 degrees) or other signs or symptoms consistent with COVID-19*Known medical history of active liver disease*Chronic Kidney Disease or have known moderate to severe renal impairment*Known human immunodeficiency virus (HIV) infection with a viral load greater than 400 copies/mL within the last 6 months or taking prohibited medications for HIV treatment*Suspected or confirmed concurrent active systemic infection*Active cancer requiring treatment with prohibited medication*Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4*Has received approved, authorized, or investigational anti-SARS-CoV-2 mAb, convalescent plasma, other drugs for treatment of COVID-19, or other anti-SARS-CoV-2 biologic products within 6 months of screening*Has received any SARS-CoV-2 vaccine within 6 months prior to screening or is expected to receive a SARS-CoV-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments through Day 38*Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19*Known or prior participation in this trial or another trial involving PF-07321332*Females who are pregnant or breastfeeding

*History SARS-CoV-2 infection*Experiencing measured fever (>38degrees) or other signs or symptoms consistent with COVID-19*Known medical history of active liver disease*Chronic Kidney Disease or have known moderate to severe renal impairment*Known human immunodeficiency virus (HIV) infection with a viral load greater than 400 copies/mL within the last 6 months or taking prohibited medications for HIV treatment*Suspected or confirmed concurrent active systemic infection*Active cancer, other than localized skin cancer*History of hypersensitivity or other contraindication to any of the components of the study intervention*Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4*Has received anti-SARS-CoV-2 mAb, convalescent plasma, other drugs for treatment of COVID-19, or other anti-SARS-CoV-2 biologic products*Has received or is expected to receive a SARS-CoV-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments during the study period*Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19*Known prior participation in this trial or other trial involving PF-07321332*Females who are pregnant or breastfeeding

*History SARS-CoV-2 infection*Experiencing measured fever (>38degrees) or other signs or symptoms consistent with COVID-19*Known medical history of active liver disease*Chronic Kidney Disease or have known moderate to severe renal impairment*Known human immunodeficiency virus (HIV) infection with a viral load greater than 400 copies/mL within the last 6 months or taking prohibited medications for HIV treatment*Suspected or confirmed concurrent active systemic infection*Active cancer, other than localized skin cancer*History of hypersensitivity or other contraindication to any of the components of the study intervention*Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4*Has received anti-SARS-CoV-2 mAb, convalescent plasma, other drugs for treatment of COVID-19, or other anti-SARS-CoV-2 biologic products*Has received or is expected to receive a SARS-CoV-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments during the study period*Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19*Known prior participation in this trial or other trial involving PF-07321332*Females who are pregnant or breastfeeding